Pembrolizumab Plus Chemotherapy Improves OS, PFS in Cervical Cancer
Cancer Network,
Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in…
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
Overview of attention for article published in Annals of Oncology, October 2024
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (89th percentile)
Readers on
- mendeley
- 50 Mendeley